TORONTO, Oct. 6, 2015 /PRNewswire/ -- Bionik Laboratories Corp. (OTCQX: BNKL), a medical device and robotics company with a focus in developing technologies and solutions for individuals with neurological disorders ("Bionik" or the "Company"), announced today that it has been included in the Kairos Society's 2015 'Kairos 50' (K50).
The Kairos Society identifies, qualifies, connects, and empowers young entrepreneurs who are building scalable solutions to the world's most complex problems. Each year they select 50 of the most promising startups from all over the world for the Kairos 50.
The seventh annual Kairos Global Summit will take place on October 13th in Hollywood, California. The Global Summit will comprise of a VIP demo day and conversations with leading VCs and industry thought-leaders.
During this invite-only event, the K50, representing the next generation of entrepreneurs making breakthroughs in the areas of biotech, education, agriculture, mobile, cleantech, healthcare, and more, will bring their cutting-edge innovations before a diverse group of global investors, industry mentors and corporate leaders.
Mr. Prywata, the Company's Chief Operating Officer, added, "We believe our patented ARKE exoskeleton is one of the most adaptable lower-body robotic devices available. ARKE's design allows users to walk more easily and efficiently and has the potential to transform the future for mobility impaired patients by significantly improving rehabilitation."
This year over 500 ventures, from almost 50 countries and across 30 industries applied for the opportunity to collaborate with today's leading corporations and investors. It is expected that over 300 mentors will attend the event, including Tim Draper (Founding Partner, Draper Fisher Jurvetson), Josh Elman (Partner, Greylock), and Robyn Ward (Head of New Media Ventures, United Talent Agency). Attendees of the Kairos Global Summit will learn what the next generation is developing and could form partnerships to bring their products and services to a global scale.
About Bionik Laboratories
Bionik Laboratories (OTCQX: BNKL) is a medical device and robotics company with a focus in developing technologies and solutions for individuals with neurological disorders. The Bionik team has researched, developed and tested its primary product, The ARKE™, a robotic lower-body exoskeleton device that allows paraplegics as well as other wheelchair users the ability to rehabilitate through walking and other motion. Bionik recently successfully raised approximately US$13.1 million which enables the company to rapidly advance its development and growth strategy. For more information, please visit www.bioniklabs.com and connect with the Company on Twitter, LinkedIn, Facebook, and Google+.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.